June 2005
Worldwide Biotech;Jun2005, Vol. 17 Issue 6, p4
Trade Publication
Reports on the presentation of data by GPC Biotech AG on its anticancer drug candidate satraplatin at the 96th Annual Meeting of the American Association for Cancer Research. Activity of satraplatin in drug-resistant tumor cells; Overview of the research plans of GPC Biotech with regard to the drug; Types of anticancer drugs resisted by drug-resistant tumor cells.


Related Articles

  • AACR Roundup.  // BioWorld Today;4/22/2009, Vol. 20 Issue 76, p5 

    The article deals with the preclinical data reported by GPC Biotech AG at the 100th Annual Meeting of the American Association for Cancer Research (AACR) on RGB-286638, a multitargeted protein kinase inhibitor. The company reported that RGB-286638 demonstrated in vivo activity in several...

  • GPC Biotech: satraplatin approval delay could prove costly.  // PharmaWatch: Monthly Review;Sep2007, Vol. 6 Issue 9, p7 

    The article reports that the New Drug Application for prostate cancer drug satraplatin was withdrawn by the GPC Biotech after an advisory panel's recommendation to wait for overall survival data before it can be approved. The GPC Biotech is making an effort to obtain the data quickly because it...

  • SURVIVAL IMPROVEMENT REPORTED IN SATRAPLATIN SPARC TRIAL.  // Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p1 

    The article reports on data from the Satraplatin and Prednisone Against Refractory Cancer (SPARC) double-blind, randomized satraplatin Phase 3 trial by GPC Biotech AG. The data, presented at the 2009 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando,...

  • Satraplatin Reverberations: GPC Cutting 63 Positions. Sheridan, Cormac // BioWorld International;2/27/2008, Vol. 13 Issue 9, p1 

    The article reports on several rounds of job cuts initiated by GPC Biotech AG following the failure of its prostate cancer drug satraplatin. The latest round of job cuts will trim the company back to just 63 employees, which will primarily affect the company's early stage research activities in...

  • Prostate Cancer Update.  // PharmaWatch: Cancer;Jun2005, Vol. 4 Issue 6, p8 

    The article offers news briefs on prostate cancer medical drug development. GPC Biotech AG has released new information on its lead drug candidate, satraplatin, declaring it to be active in drug-resistant tumor cells and to demonstrate a synergistic effect when used with Taxotere by...

  • GPC Biotech presents new data supporting efficacy of anticancer monoclonal antibody.  // PharmaWatch: Biotechnology;October 2003, Vol. 2 Issue 10, p8 

    Reports on data presented by GPC Biotech AG on its anticancer monoclonal antibody, 1D09C3. Evaluation of the antibody in combination with Rituxan in an in vivo non-Hodgkin's lymphoma model; Synergistic effect of the two antibodies; Comparison of the cure rate of the combination therapy with...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;11/3/2003, Vol. 264 Issue 15, p10 

    Reports developments in the pharmaceutical industry as of November 2003. Letter of approval received by Andrx Corp. for its Fortamet tablets; Deal between Atlanta officials and GPC Biotech AG.

  • Novel Anticancer Drug on Track.  // Chemical Market Reporter;9/29/2003, Vol. 264 Issue 10, p10 

    Announces the first trade status given by the U.S. Food and Drug Administration to the anticancer drug satraplatin, developed by GPC Biotech AG.

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Sep2007, Vol. 6 Issue 9, p4 

    The article offers news briefs related to cancer. Enzon Pharmaceuticals has listed several patients in two Phase 1 studies of its cancer drug candidate. GPC Biotech has withdrawn its drug application for prostate cancer drug satraplatin. ImClone Systems and Bristol-Myers Squibb have improved the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics